Axonics reports third quarter 2023 financial results

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended september 30, 2023. “our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter,” said raymond w. cohen, chief executive officer. “our growth was driven by higher utilization and.
AXNX Ratings Summary
AXNX Quant Ranking